development of long-acting interferon as new therapy for pv and et
Published 9 years ago • 1.1K plays • Length 12:24Download video MP4
Download video MP3
Similar videos
-
13:09
long-acting interferon: what is the difference?
-
22:00
update on long-acting interferons for mpn
-
16:28
update on long-acting interferons for mpn
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
15:06
ropeginterferon, welcome to the us
-
6:19
management of patients with pv who are intolerant to interferon and who develop post-polycythemic mf
-
1:42
dr. yacoub on pegylated interferon treatment for pv
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
19:42
management of pv, the role of interferon
-
4:28
management of pv, the role of interferon
-
2:55
interferons and myeloproliferative neoplasms (mpns)
-
28:23
dr raajit rampal-interferon and new mpn therapies
-
5:17
determining the potential of ropeginterferon alfa-2b in polycythemia vera
-
6:15
interferon’s role in treating polycythemia vera
-
24:52
combination therapy with jak2 inhibitors in mpn
-
21:29
topical challenges in the management of et
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
17:25
case study: inadequately controlled polycythemia vera (pv)